Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance

Table 1 Expression of Cyr61, CTGF and Nov mRNA in HCC and para-cancerous liver tissues (mean ± SD)

	n	Cyr61	CTGF	Nov
HCC	31	2.34 ± 0.46b	2.21 ± 0.34b	1.56 ± 0.21
Para-cancerous	31	0.48 ± 0.29	0.65 ± 0.33	0.89 ± 0.64

^bP < 0.01 vs para-cancerous tissues.

Table 2 Relationship between Cyr61, CTGF and Nov mRNA expressions and clinicopathological features (mean ± SD)

	n	Cyr61	P	CTGF	P	Nov	P
PV thrombosis
Present	16	2.59 ± 0.41	0.024	2.41 ± 0.39	0.031	1.45 ± 0.56	0.147
Absent	15	2.08 ± 0.65		2.10 ± 0.58		1.56 ± 0.45
AFP level
≤ 20 ng/mL	19	2.26 ± 0.48	0.068	2.21 ± 0.20	0.063	1.38 ± 0.43	0.241
> 20 ng/mL	12	2.36 ± 0.71		2.23 ± 0.84		1.66 ± 0.71
Tumor size (cm)
≤ 5 cm	20	2.35 ± 0.86	0.124	2.26 ± 0.79	0.071	1.59 ± 0.58	0.251
> 5 cm	11	2.32 ± 0.41		2.09 ± 0.53		1.55 ± 0.31
Capsule formation
Positive	18	2.35 ± 0.34	0.136	2.31 ± 0.34	0.132	1.87 ± 0.65	0.135
Negative	13	2.33 ± 0.67		2.15 ± 0.87		1.36 ± 0.81
Histological grade
I-II	13	2.21 ± 0.39	0.052	1.89 ± 0.54	0.022	1.35 ± 0.47	0.132
III-IV	18	2.51 ± 0.41		2.51 ± 0.61		1.58 ± 0.68

PV: portal vein.

Table 3 Pathological features of three types of HCC

Pathological features	n	SHCC (n = 11)	NHCC (n = 12)	SLHCC (n = 8)
Microvascular invasion
Present	16	3	10	3a
Absent	15	8	2	5
Capsule formation
Present	18	8	4	6
Absent	13	3	8	2
Edmondson’s classification
I-II	13	7	1	5a
III-IV	18	4	11	3
Liver cirrhosis
Present	9	4	9	2
Absent	22	7	3	6
AFP consentration
≤ 20 ng/mL	19	6	9	4
> 20 ng/mL	12	5	3	4

^aP < 0.05 vs NHCC.

Table 4 Cyr61, CTGF and Nov mRNA expressions in three types of HCCs

HCC	n	Cyr61	P	CTGF	P	Nov	P
SLHCC	8	2.22 ± 0.36		2.09 ± 0.44		1.52 ± 0.41
NHCC	12	2.51 ± 0.53	0.037a	2.38 ± 0.29	0.043a	1.58 ± 0.36	0.287
SHCC	11	2.18 ± 0.42		2.03 ± 0.31		1.46 ± 0.19

^aP < 0.05 vs SLHCC.